EA201892486A1 - Способ получения соединения диарилтиогидантоина - Google Patents

Способ получения соединения диарилтиогидантоина

Info

Publication number
EA201892486A1
EA201892486A1 EA201892486A EA201892486A EA201892486A1 EA 201892486 A1 EA201892486 A1 EA 201892486A1 EA 201892486 A EA201892486 A EA 201892486A EA 201892486 A EA201892486 A EA 201892486A EA 201892486 A1 EA201892486 A1 EA 201892486A1
Authority
EA
Eurasian Patent Office
Prior art keywords
producing
diarylthiohydantoin compound
compound
diarylthiohydantoin
intermediates
Prior art date
Application number
EA201892486A
Other languages
English (en)
Inventor
Сирил Бен Хаим
Андраш Хорват
Йохан Эрвин Эдмонд Вертс
Original Assignee
Арагон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арагон Фармасьютикалз, Инк. filed Critical Арагон Фармасьютикалз, Инк.
Publication of EA201892486A1 publication Critical patent/EA201892486A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/14—Phosphorus; Compounds thereof
    • B01J27/186—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
    • B01J27/195—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium with vanadium, niobium or tantalum
    • B01J27/198—Vanadium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
    • B01J37/04—Mixing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Описаны способы и промежуточные соединения для получения соединения (X), которое в настоящее время исследуют для лечения рака предстательной железы.
EA201892486A 2014-12-19 2015-12-17 Способ получения соединения диарилтиогидантоина EA201892486A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462094436P 2014-12-19 2014-12-19

Publications (1)

Publication Number Publication Date
EA201892486A1 true EA201892486A1 (ru) 2019-07-31

Family

ID=55168400

Family Applications (4)

Application Number Title Priority Date Filing Date
EA201892486A EA201892486A1 (ru) 2014-12-19 2015-12-17 Способ получения соединения диарилтиогидантоина
EA201791390A EA201791390A1 (ru) 2014-12-19 2015-12-17 Способ получения соединения диарилтиогидантоина
EA201892485A EA201892485A1 (ru) 2014-12-19 2015-12-17 Способ получения соединения диарилтиогидантоина
EA201892487A EA201892487A1 (ru) 2014-12-19 2015-12-17 Способ получения соединения диарилтиогидантоина

Family Applications After (3)

Application Number Title Priority Date Filing Date
EA201791390A EA201791390A1 (ru) 2014-12-19 2015-12-17 Способ получения соединения диарилтиогидантоина
EA201892485A EA201892485A1 (ru) 2014-12-19 2015-12-17 Способ получения соединения диарилтиогидантоина
EA201892487A EA201892487A1 (ru) 2014-12-19 2015-12-17 Способ получения соединения диарилтиогидантоина

Country Status (33)

Country Link
US (1) US9688655B2 (ru)
EP (4) EP3372586A1 (ru)
JP (2) JP6681902B2 (ru)
KR (1) KR102586059B1 (ru)
CN (1) CN107108507B (ru)
AR (1) AR103228A1 (ru)
AU (1) AU2015364537B2 (ru)
BR (1) BR112017013113B1 (ru)
CA (1) CA2970937A1 (ru)
CY (2) CY1121684T1 (ru)
DK (3) DK3372584T5 (ru)
EA (4) EA201892486A1 (ru)
ES (3) ES2827549T3 (ru)
HR (3) HRP20220750T1 (ru)
HU (2) HUE052475T2 (ru)
IL (1) IL252843A0 (ru)
LT (3) LT3233803T (ru)
MA (1) MA41200B1 (ru)
MD (1) MD3233803T2 (ru)
ME (1) ME03420B (ru)
MX (1) MX2017008179A (ru)
NZ (1) NZ732766A (ru)
PH (1) PH12017501152A1 (ru)
PL (3) PL3372585T3 (ru)
PT (3) PT3372585T (ru)
RS (3) RS63455B1 (ru)
SG (4) SG10201912805SA (ru)
SI (3) SI3233803T1 (ru)
TR (1) TR201904739T4 (ru)
TW (4) TWI683810B (ru)
UA (1) UA123201C2 (ru)
WO (1) WO2016100652A2 (ru)
ZA (1) ZA201704877B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA029666B1 (ru) 2014-12-19 2018-04-30 Арагон Фармасьютикалз, Инк. Способы получения соединения диарилтиогидантоин
ES2827549T3 (es) * 2014-12-19 2021-05-21 Aragon Pharmaceuticals Inc Proceso para la preparación de un compuesto de diariltiohidantoina
CN108069869B (zh) * 2016-11-09 2022-03-01 上海医药工业研究院 一种Apalutamide的制备方法及其中间体
TW201831461A (zh) * 2017-01-18 2018-09-01 台灣神隆股份有限公司 製備阿帕魯醯胺的方法
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN107501237B (zh) * 2017-08-17 2022-03-22 上海西浦医药科技有限公司 一种Apalutamide的合成方法
CN108383749B (zh) * 2018-01-30 2021-03-09 杭州科巢生物科技有限公司 阿帕鲁胺的合成方法及其中间体
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
CN108314646B (zh) * 2018-04-11 2021-03-19 武汉慧敏科技中心 一种高分散双金属纳米材料制备泌尿生殖系统用药物中间体的方法
CN109651256A (zh) * 2018-11-20 2019-04-19 上海健康医学院 一种式（viii）的恩杂鲁胺的制备方法
CN110511206A (zh) * 2019-06-17 2019-11-29 扬子江药业集团江苏海慈生物药业有限公司 芳基-2-硫代海因类化合物中间体、其制备方法及应用
CN110511207A (zh) * 2019-06-17 2019-11-29 扬子江药业集团江苏海慈生物药业有限公司 芳基-2-硫代海因类化合物中间体、其制备方法及应用
WO2022049265A1 (en) 2020-09-04 2022-03-10 Synthon B.V. Improved process for preparation of apalutamide
CN113292535B (zh) * 2021-06-18 2022-07-01 南京方生和医药科技有限公司 一种制备阿帕鲁胺中间体及阿帕鲁胺的方法
CN113402466B (zh) * 2021-06-18 2022-08-16 南京方生和医药科技有限公司 一种阿帕鲁胺中间体及制备阿帕鲁胺的方法
CN115850233A (zh) * 2021-09-24 2023-03-28 南京方生和医药科技有限公司 一种阿帕鲁胺的合成方法
CN115536634A (zh) * 2022-10-17 2022-12-30 上海博悦生物科技有限公司 一种阿帕他胺的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
TWI263640B (en) * 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP2656842B1 (en) * 2006-03-27 2016-08-10 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
US8461343B2 (en) * 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
EP2294053B1 (en) * 2008-05-16 2016-01-06 Takeda California, Inc. Glucokinase activators
MX2012006615A (es) * 2009-12-11 2012-10-05 Autifony Therapeuticts Ltd Derivados de imidazolidinodiona.
PT3124481T (pt) * 2010-02-16 2018-06-18 Aragon Pharmaceuticals Inc Moduladores do receptor de androgénios e suas utilizações
EP3329775B1 (en) * 2010-02-24 2021-04-21 Medivation Prostate Therapeutics LLC Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds
BR112013023028B1 (pt) * 2011-03-10 2021-09-21 Suzhou Kintor Pharmaceuticals, Inc Composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e formulação farmacêutica tópica
WO2013029338A1 (en) * 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
CA2908236C (en) * 2012-03-29 2021-10-26 Schindler, William Diaspirin crosslinked pegylated hemoglobin
JP6469092B2 (ja) * 2013-05-29 2019-02-13 ヒノバ ファーマシューティカルズ インコーポレイテッド イミダゾリジンジオン化合物及び薬物組成物
ES2827549T3 (es) * 2014-12-19 2021-05-21 Aragon Pharmaceuticals Inc Proceso para la preparación de un compuesto de diariltiohidantoina

Also Published As

Publication number Publication date
CY1121684T1 (el) 2020-07-31
SI3372585T1 (sl) 2022-08-31
CN107108507A (zh) 2017-08-29
PH12017501152A1 (en) 2017-11-27
PL3372584T3 (pl) 2021-07-05
JP6681902B2 (ja) 2020-04-15
DK3233803T3 (en) 2019-04-08
JP2018501237A (ja) 2018-01-18
MX2017008179A (es) 2017-09-18
TW202031639A (zh) 2020-09-01
EP3372584B1 (en) 2020-09-23
PT3372585T (pt) 2022-07-08
LT3233803T (lt) 2019-04-10
EP3233803B1 (en) 2019-01-30
TWI683810B (zh) 2020-02-01
BR112017013113B1 (pt) 2023-11-21
TWI703132B (zh) 2020-09-01
TW201945342A (zh) 2019-12-01
UA123201C2 (uk) 2021-03-03
US20160176845A1 (en) 2016-06-23
HRP20201847T1 (hr) 2021-03-19
NZ732766A (en) 2023-07-28
KR102586059B1 (ko) 2023-10-05
MA41200B1 (fr) 2019-05-31
IL252843A0 (en) 2017-08-31
RS63455B1 (sr) 2022-08-31
ES2827549T9 (es) 2021-07-02
EP3372585A1 (en) 2018-09-12
JP2020114842A (ja) 2020-07-30
MD3233803T2 (ro) 2019-07-31
SG11201704969QA (en) 2017-07-28
DK3372584T5 (da) 2021-05-17
SG10201912805SA (en) 2020-02-27
US9688655B2 (en) 2017-06-27
CN107108507B (zh) 2024-05-28
EP3372586A1 (en) 2018-09-12
CY1123611T1 (el) 2022-03-24
LT3372584T (lt) 2020-12-10
EA201892487A1 (ru) 2019-07-31
HRP20220750T1 (hr) 2022-09-02
EP3372584B9 (en) 2021-03-31
ME03420B (me) 2020-01-20
CA2970937A1 (en) 2016-06-23
KR20170095976A (ko) 2017-08-23
SG10201912811QA (en) 2020-02-27
RS61060B1 (sr) 2020-12-31
ES2919951T3 (es) 2022-07-29
RS61060B9 (sr) 2021-07-30
WO2016100652A3 (en) 2016-08-25
DK3372584T3 (da) 2021-01-04
AU2015364537B2 (en) 2020-10-08
JP6903785B2 (ja) 2021-07-14
PT3233803T (pt) 2019-05-20
WO2016100652A2 (en) 2016-06-23
ES2718539T3 (es) 2019-07-02
PL3233803T3 (pl) 2019-07-31
HUE042409T2 (hu) 2019-06-28
MA41200A (fr) 2017-10-25
AU2015364537A1 (en) 2017-07-06
TR201904739T4 (tr) 2019-05-21
PL3372585T3 (pl) 2022-10-10
TW201639825A (zh) 2016-11-16
HUE052475T2 (hu) 2021-05-28
PT3372584T (pt) 2020-11-13
SI3233803T1 (sl) 2019-05-31
TW201945343A (zh) 2019-12-01
EP3372584A1 (en) 2018-09-12
DK3372585T3 (da) 2022-05-30
SG10201912802XA (en) 2020-02-27
TWI753336B (zh) 2022-01-21
AR103228A1 (es) 2017-04-26
SI3372584T1 (sl) 2021-08-31
BR112017013113A2 (pt) 2017-12-26
RS58454B1 (sr) 2019-04-30
ES2827549T3 (es) 2021-05-21
LT3372585T (lt) 2022-07-11
EP3233803A2 (en) 2017-10-25
EA201892485A1 (ru) 2019-07-31
HRP20190540T1 (hr) 2019-06-14
HRP20201847T2 (hr) 2021-05-28
TWI689494B (zh) 2020-04-01
EP3372585B1 (en) 2022-03-30
EA201791390A1 (ru) 2017-10-31
ZA201704877B (en) 2019-02-27

Similar Documents

Publication Publication Date Title
EA201892487A1 (ru) Способ получения соединения диарилтиогидантоина
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201791391A1 (ru) Способы получения соединения диарилтиогидантоин
EA201791208A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
EA201790413A1 (ru) Антитела против tigit
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
EA201692100A1 (ru) Новые антитела против rnf43 и способы их применения
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
EA201691632A1 (ru) Пиразины в качестве модуляторов gpr6
EA201691203A1 (ru) Твёрдые формы тенофовира
EA201792282A1 (ru) Способы лечения заболеваний
MX2019003311A (es) Metodos para tratamiento de cancer de ovario.
EP3442555A4 (en) METHODS OF TREATING BREAST CANCER
EA201992022A1 (ru) Терапевтическая рнк
AU2016902922A0 (en) Methods of Treating Cancer (I)
AU2016902923A0 (en) Methods of Treating Cancer (II)